Vendor Intelligence Report: Royal Peptides

Published 13 Jun 2026. 25-page investigative report on who is behind Royal Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Royal Peptides is a product-specific call, not a vendor-wide yes or no. Across 31 Finnrick lab tests, Royal Peptides has 22 pass / 9 fail, a 71% overall pass rate. Tirzepatide is the strongest tested option and Semaglutide is comparatively favorable; Retatrutide is the weak point, with a severe 40mg short-fill event and a second short-fill in the same format. Ratings fall under stricter fill-sensitive grading, so purity/identity comfort should not be confused with label-quantity confidence.

The OSINT record is thinner than the institutional posture. The site claims a 2023 origin, named fulfillment hubs, and Royal Labs umbrella branding; RDAP, archive, and registry records tell a different story, with no matching entity located in searched registries, iCloud-routed business email, and a single 520-area contact channel. That does not rule out a DBA or third-party logistics, but it leaves buyers without a verifiable operator identity.

Sourcing and reputation signals are mixed. A 2024 Wix archive named Chinese manufacturing partners; the current WooCommerce site removes that list while warning that COAs may show upstream manufacturers, aliases, or distributors instead of Royal Peptides. A sister wholesale site shares contact details, copycat/lookalike domains complicate verification, and the affiliate scan found a mostly undisclosed coupon/referral layer, including a same-day peptide-code coupon cluster.

Inside the full report:

  • Product-level Finnrick analysis and methodology-divergence charts for Retatrutide, Tirzepatide, and Semaglutide
  • Retatrutide 40mg short-fill case review and chain-of-custody implications
  • Registry, RDAP, DNS, hosting, MX, and policy evidence behind the corporate-identity assessment
  • Wayback comparison of the 2024 Wix supplier disclosure against current sourcing and COA language
  • Affiliate/coupon scan across X posts, ProfPeptide/Peptide Codes activity, Reddit leads, and coupon aggregators
  • Official-domain, sister-site, copycat, and related-domain verification controls

Risk assessment

  • Retatrutide dosing-inconsistency risk — high: Retatrutide has 14 tests with 8 pass / 6 fail and a 68.44% Finnrick rating; a Jan 29, 2026 40mg vial contained 11.4mg, with another 40mg short-fill on Mar 1, 2026.
  • Corporate-history and identity misrepresentation risk — high: The site claims a 2023 establishment date and multi-hub operations, while RDAP shows Aug 20, 2024 domain creation and searched registries produced no matching public entity or owners.
  • Tirzepatide dosing-variability risk — medium: Tirzepatide is Royal Peptides’ strongest tested product at 79.96% with 10 tests and 8 pass / 2 fail, but the lab trail still shows meaningful batch-to-batch fill variability.
  • Supply-chain obfuscation risk — medium: The 2024 Wix site disclosed Chinese peptide sourcing and ten partner names; the current site removed those names and says COAs may show upstream aliases.
  • Unlabeled-vial and chain-of-custody risk — medium: Many Finnrick-submitted samples were unlabeled or minimally identified, and the small buyer survey scored packaging quality 3.6 / 5, weakening vial-to-COA traceability.
  • Undisclosed affiliate-promotion risk — medium: The affiliate scan found 20 promoter or mention records; most referral, coupon, or commerce-linked placements lacked clear disclosure.
  • Copycat and brand-confusion risk — medium: royalpeptidesusa.com, royalpeptides.ca, Royal Peptides USA social branding, and coupon subdomains create confusion; the vendor warning helps but verification controls remain incomplete.